The predictive value of treatment response after neoadjuvant therapy
The Immune Landscape of Residual TNBC After Neoadjuvant Chemotherapy
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer
Practical approach to the management of the axilla after neoadjuvant chemotherapy
The meaning of residual disease in breast cancer
Evaluation of Breast Specimens after Neoadjuvant Chemotherapy
Tackling residual disease in breast cancer
Capecitabine remains the adjuvant standard of care for TNBC with residual disease | Ingrid Mayer
Exploratory analysis of KEYNOTE-522: EFS after neoadjuvant pembro + chemo Vs chemo for early TNBC
No pCR in Patients After Neoadjuvant Chemotherapy in TNBC
Dr. Tereffe on Treatment After Neoadjuvant Chemotherapy in Breast Cancer
Value of Circulating Tumor DNA After Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
What do we do after complete response to neoadjuvant therapy?
Axillary dissection vs radiation for residual nodal disease after neoadjuvant systemic therapy
SOLTI-1503 PROMETEO: T-VEC + atezolizumab in patients with residual BC after neoadjuvant chemo
Dr. Farhad Ravandi on How to Treat Minimal Residual Disease
Case 1: Adjuvant Therapy for Residual Disease in HER2+ Breast Cancer
ALTERNATE: neoadjuvant chemotherapy in ER+ HER2- breast cancer
